Citations

Clear

1446 citation(s) found for "Howard, F".

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer
Renfro, Lindsay A. , Hurwitz, Herbert I. , Safran, Howard , Guarino, Michael J., Kim, George P., Hecht, J. Randolph, Weil, Susan C., Heyburn, John, Schweizer, Charles, O’Shannessy, Daniel J., Díaz, Luis A. , Diaz, Luis A , Grothey, Axel , Strosberg, Jonathan , Marshall, John L , Wang, Wenquan

Mayo Clinic

Clinical Cancer Research | October 30, 2017 | Volume: 24 | Issue: 2 | Pages: 316-325

10.1158/1078-0432.ccr-17-1558 | PMID 29084918 Get It

Abstract Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer and to identify a responsive patient population based on biomarkers. Experimental Design: This was a randomized, double-blind, placebo-controlled, phase II study. Patients were randomly assigned in a 2:1 ratio to receive weekly intravenous ontuxizumab (8 mg/kg) or placebo plus best supportive care until progression or unacceptable toxicity. Tissue and blood biomarkers were evaluated for their ability to identify a patient population that was responsive to ontuxizumab. Results: A total of 126 patients were enrolled. No significant difference between the ontuxizumab and placebo groups was evident for the primary endpoint of progression-free survival (PFS), with a median PFS of 8.1 weeks in each group (HR, 1.13; 95% confidence interval, 0.76–1.67; P = 0.53). There were no significant differences between groups for overall survival (OS) or overall response rate (ORR). The most common treatment-emergent adverse events (TEAEs) in the ontuxizumab group (vs. the placebo group, respectively) were fatigue (53.7% vs. 47.5%), nausea (39.0% vs. 35.0%), decreased appetite (34.1% vs. 27.5%), and constipation (28.0% vs. 32.5%). The most common grade 3/4 TEAE in the ontuxizumab group versus placebo was back pain (11.0% vs. 0%). No single biomarker clearly identified patients responsive to ontuxizumab. Conclusions: No benefit with ontuxizumab monotherapy compared with placebo for clinical response parameters of PFS, OS, or ORR was demonstrated. Ontuxizumab was well tolerated. Clin Cancer Res; 24(2); 316–25. ©2017 AACR.
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Tran, Nhan L. , Halperin, Rebecca F. , Phillips, Joanna J. , Kuhn, John G. , Groot, John F. de, Colman, Howard , Wen, Patrick Y. , Mellinghoff, Ingo K. , Butowski, Nicholas , Taylor, Jennie , Clarke, Jennifer , Chang, Susan M. , Molinaro, Annette M. , Maggiora, Gerald M. , Peng, Sen, Liang, Winnie S. , Trent, Jeffrey M. , Berens, Michael E. , Carpten, John D. , Craig, David W. , Prados, Michael D. , Berens, Michael E , Byron, Sara A. , Colman, Howard , Ligon, Keith L , Wen, Patrick Yung , Cloughesy, Timothy F. , Chang, Susan Marina , Berger, Mitchel S. , Molinaro, Annette M. , Nasser, Sara A. , Mellinghoff, Ingo K , Tran, Nhan L

Mayo Clinic

Clinical Cancer Research | October 26, 2017 | Volume: 24 | Issue: 2 | Pages: 295-305

10.1158/1078-0432.ccr-17-0963 | PMID 29074604 Get It

Abstract Purpose: Glioblastoma is an aggressive and molecularly heterogeneous cancer with few effective treatment options. We hypothesized that next-generation sequencing can be used to guide treatment recommendations within a clinically acceptable time frame following surgery for patients with recurrent glioblastoma. Experimental Design: We conducted a prospective genomics-informed feasibility trial in adults with recurrent and progressive glioblastoma. Following surgical resection, genome-wide tumor/normal exome sequencing and tumor RNA sequencing were performed to identify molecular targets for potential matched therapy. A multidisciplinary molecular tumor board issued treatment recommendations based on the genomic results, blood–brain barrier penetration of the indicated therapies, drug–drug interactions, and drug safety profiles. Feasibility of generating genomics-informed treatment recommendations within 35 days of surgery was assessed. Results: Of the 20 patients enrolled in the study, 16 patients had sufficient tumor tissue for analysis. Exome sequencing was completed for all patients, and RNA sequencing was completed for 14 patients. Treatment recommendations were provided within the study's feasibility time frame for 15 of 16 (94%) patients. Seven patients received treatment based on the tumor board recommendations. Two patients reached 12-month progression-free survival, both adhering to treatments based on the molecular profiling results. One patient remained on treatment and progression free 21 months after surgery, 3 times longer than the patient's previous time to progression. Analysis of matched nonenhancing tissue from 12 patients revealed overlapping as well as novel putatively actionable genomic alterations. Conclusions: Use of genome-wide molecular profiling is feasible and can be informative for guiding real-time, central nervous system–penetrant, genomics-informed treatment recommendations for patients with recurrent glioblastoma. Clin Cancer Res; 24(2); 295–305. ©2017 AACR. See related commentary by Wick and Kessler, p. 256
[P4–016]: A STUDY TO MODEL RATES OF CHANGE ON NEUROPSYCHOLOGICAL TEST MEASURES IN SUBJECTS DIAGNOSED WITH BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AND HEALTHY SUBJECTS
Ratti, Elena , Jaeger, Judith , Huang, Ellen , Petrillo, Jennifer , Wager, Carrie, Boxer, Adam L. , Kramer, Joel H. , Rosen, Howard J. , Boeve, Bradley F. , Rosenstiel, Philipp von

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_26 | Pages: No page available

10.1016/j.jalz.2017.06.1880 Get It

[P2–261]: GHRELIN, AMYLIN, GASTRIC INHIBITORY PEPTIDE AND COGNITION IN MIDDLE‐AGED HIV‐INFECTED AND UNINFECTED WOMEN: THE WOMEN's INTERAGENCY HIV STUDY
Gustafson, Deborah , McFarlane, Samy I. , Uglialoro, Anthony D., Holman, Susan, Crystal, Howard, Mielke, Michelle M. , Keating, Sheila M. , MINKOFF, HOWARD L.

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_14 | Pages: No page available

10.1016/j.jalz.2017.06.914 Get It